tldrdailynews.com logo

Omeros Abandons Kidney Disease Therapy After Failed Trial

1 min read
Source: Endpoints News
Omeros Abandons Kidney Disease Therapy After Failed Trial
Photo: Endpoints News
TL;DR

Omeros' drug candidate for immunoglobulin A nephropathy (IgAN) failed a Phase III study, causing the company's stock price to drop by nearly half. The late-stage failure is a setback for Omeros' pipeline-in-a-product plans for narsoplimab, and as a result, the ARTEMIS-IGAN study will be discontinued. The trial did not achieve statistical significance in reducing elevated protein levels in urine compared to the placebo.

Topics:businesshealthcare#healthcare#immunoglobulin-a-nephropathy#kidney-disease#narsoplimab#omeros#phase-iii-trial
Share this article
  1. Omeros drug fails a PhIII kidney trial, stock nearly halved  Endpoints News
  2. UPDATE 1-Omeros to terminate kidney disease trial as therapy fails late-stage study  Yahoo Finance
  3. Omeros stops kidney disease phase 3 after interim review fail, cutting thread holding up stock price  FierceBiotech
  4. Omeros terminates development of kidney disease therapy after study failure  Reuters
  5. View Full Coverage on Google News

Want the full story? Read the original reporting

Read on Endpoints News